2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. nAChR
  4. Vecuronium bromide

Vecuronium bromide  (Synonyms: ORG NC 45)

Cat. No.: HY-B0118A Purity: ≥98.0%
COA Handling Instructions

Molarity Calculator

Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia.

For research use only. We do not sell to patients.

Vecuronium bromide Chemical Structure

Vecuronium bromide Chemical Structure

CAS No. : 50700-72-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 88 In-stock
Solution
10 mM * 1 mL in DMSO USD 88 In-stock
Solid
50 mg USD 115 In-stock
100 mg USD 165 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Vecuronium bromide:

Vecuronium bromide Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia[1][2].

In Vitro

Vecuronium bromide (0-100 μM, 15 min) inhibits [3H] norepinephrine (NE) uptake to 65% at 100 μM in adrenal medullary cells[1].
Vecuronium bromide (0-15 μM,72 hours) inhibits cancer cell proliferation and migration in a concentration-dependent manner[2].
Vecuronium bromide (0-15 μM,72 hours) can significantly reduce cell viability by combining with cisplatin[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vecuronium bromide Related Antibodies

Cell Proliferation Assay[2]

Cell Line: Lung cancer cell line (A549)
Concentration: 0-15 μM
Incubation Time: 72 hours
Result: Inhibited cell proliferation at concentrations ranging from 5.0 μM to 15 μM.

Cell Cytotoxicity Assay[2]

Cell Line: Lung cancer cell line (A549)
Concentration: 0-15 μM
Incubation Time: 72 hours
Result: Resulted in a decrease in cell viability from 10 μM to 15 Μm by combining with cisplatin.
In Vivo

Vecuronium bromide (Intravenous injection, 0-5 μM, every 30 min, 2 hours) attenuates the response of carotid sinus nerve activity (CSNA) to hypoxia in a dose-dependent manner and inhibits the neural response of the carotid body to acetylcholine (ACh) in Wister rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wister rats weighing 250-350 g[3]
Dosage: 0-5 μM
Administration: Intravenous injection; every 30 min; 2 hours
Result: Significantly diminished CSNA response to hypoxia at the concentration of 5 μM and reduced carotid sinus nerve response to ACh at 0.5 μM.
Clinical Trial
Molecular Weight

637.73

Formula

C34H57BrN2O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2[N+]3(CCCCC3)C)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CCCCC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (156.81 mM)

DMSO : ≥ 46 mg/mL (72.13 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5681 mL 7.8403 mL 15.6806 mL
5 mM 0.3136 mL 1.5681 mL 3.1361 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (3.26 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (3.26 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 1.5681 mL 7.8403 mL 15.6806 mL 39.2015 mL
5 mM 0.3136 mL 1.5681 mL 3.1361 mL 7.8403 mL
10 mM 0.1568 mL 0.7840 mL 1.5681 mL 3.9202 mL
15 mM 0.1045 mL 0.5227 mL 1.0454 mL 2.6134 mL
20 mM 0.0784 mL 0.3920 mL 0.7840 mL 1.9601 mL
25 mM 0.0627 mL 0.3136 mL 0.6272 mL 1.5681 mL
30 mM 0.0523 mL 0.2613 mL 0.5227 mL 1.3067 mL
40 mM 0.0392 mL 0.1960 mL 0.3920 mL 0.9800 mL
50 mM 0.0314 mL 0.1568 mL 0.3136 mL 0.7840 mL
60 mM 0.0261 mL 0.1307 mL 0.2613 mL 0.6534 mL
H2O 80 mM 0.0196 mL 0.0980 mL 0.1960 mL 0.4900 mL
100 mM 0.0157 mL 0.0784 mL 0.1568 mL 0.3920 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vecuronium bromide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vecuronium50700-72-6ORG NC 45ORG NC45ORG NC-45nAChRNicotinic acetylcholine receptorsnAChR inhibitormuscle relaxantcancerneurological diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vecuronium bromide
Cat. No.:
HY-B0118A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.